<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21268">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02829996</url>
  </required_header>
  <id_info>
    <org_study_id>IPC-02-2015</org_study_id>
    <nct_id>NCT02829996</nct_id>
  </id_info>
  <brief_title>Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma</brief_title>
  <official_title>Phase II, Randomized, Double-masked, Active-controlled Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Subjects With Ocular Hypertension or Primary Open-Angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inotek Pharmaceuticals Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inotek Pharmaceuticals Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II, randomized, double-masked study to evaluate the efficacy and tolerability of
      topical ocular delivery of fixed-dosed combinations of trabodenoson and latanoprost in
      subjects with Ocular Hypertension or Primary Open-Angle Glaucoma.

      All subjects who meet the study's enrollment criteria following Screening will undergo
      washout of all prohibited medications (if washout is needed), including their routine
      glaucoma medications. During the Placebo Run-In Period, placebo is applied twice daily to
      both eyes in all subjects. During the Treatment Period, study drug is applied to both eyes
      for a total of 8 weeks. Each subject will be assigned 4 weeks of AM and 4 weeks of PM dosing
      in a masked manner. AM vs PM dosing is masked utilizing Placebo in addition to the active
      drug product. During the Treatment Period, study drug (Active and Placebo) eye drop
      applications will occur twice daily, in the morning and in the evening. The Treatment Period
      will be followed by an Observation Period of approximately 7 days wherein no study eye drops
      are instilled.

      The purpose of the study is to assess the overall benefit/risk profile of binocular topical
      application of different doses of trabodenoson (3.0% and 6.0%) when combined with
      latanoprost (0.005% or 0.0025%) one drop daily (QD) for 8 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Intraocular Pressure (IOP)</measure>
    <time_frame>Two Months</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Safety Parameters, including treatment emergent adverse events, to assess tolerability and safety.</measure>
    <time_frame>Through Study Completion, up to 9 weeks.</time_frame>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">165</enrollment>
  <condition>Primary Open-Angle Glaucoma (POAG)</condition>
  <condition>Ocular Hypertension (OHT)</condition>
  <arm_group>
    <arm_group_label>trabodenoson 6.0% / latanoprost 0.005% QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>trabodenoson 6.0% / latanoprost 0.005% Fixed-Dose Combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>trabodenoson 3.0% / latanoprost 0.005% QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>trabodenoson 3.0% / latanoprost 0.005% Fixed-Dose Combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>trabodenoson 6.0% / latanoprost 0.0025% QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>trabodenoson 6.0% / latanoprost 0.0025% Fixed-Dose Combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>latanoprost 0.005% QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>latanoprost 0.005% ophthalmic solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>latanoprost 0.0025% QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>latanoprost 0.0025% ophthalmic solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trabodenoson 6.0% / latanoprost 0.005% QD</intervention_name>
    <description>Trabodenoson 6.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.</description>
    <arm_group_label>trabodenoson 6.0% / latanoprost 0.005% QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trabodenoson 3.0% / latanoprost 0.005% QD</intervention_name>
    <description>Trabodenoson 3.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.</description>
    <arm_group_label>trabodenoson 3.0% / latanoprost 0.005% QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trabodenoson 6.0% / latanoprost 0.0025% QD</intervention_name>
    <description>Trabodenoson 6.0% / latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.</description>
    <arm_group_label>trabodenoson 6.0% / latanoprost 0.0025% QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>latanoprost 0.005% QD</intervention_name>
    <description>Latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.</description>
    <arm_group_label>latanoprost 0.005% QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>latanoprost 0.0025% QD</intervention_name>
    <description>Latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.</description>
    <arm_group_label>latanoprost 0.0025% QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of ocular hypertension (OHT) or primary open-angle glaucoma (POAG)

          -  Mean Intraocular pressure (IOP) of ≥25 and ≤34

        Exclusion Criteria:

          -  Significant visual field loss or any new field loss within the past year

          -  Cup-to-disc ratio &gt;0.8

          -  Central corneal thickness &lt;490 µm or &gt;610 µm

          -  A recent (acute) or chronic medical condition that might obfuscate the Subject's
             study data
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cadmus C Rich, MD,MBA,CPE</last_name>
    <role>Study Director</role>
    <affiliation>Inotek Pharmaceuticals Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Feinberg</last_name>
    <phone>781-676-2112</phone>
    <email>tfeinberg@inotekpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Inotek Pharmaceuticals Corporation</name>
      <address>
        <city>Lexington</city>
        <state>Massachusetts</state>
        <zip>02421</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 25, 2016</lastchanged_date>
  <firstreceived_date>July 8, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glaucoma</keyword>
  <keyword>primary open-angle glaucoma</keyword>
  <keyword>ocular hypertension</keyword>
  <keyword>adenosine agonist</keyword>
  <keyword>eye drop</keyword>
  <keyword>trabodenoson</keyword>
  <keyword>trabecular meshwork</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Latanoprost</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
